Eli Lilly Corp. diskutieren
Eli Lilly Corp.
WKN: 858560 / Symbol: LLY / Name: Eli Lilly / Aktie / Pharmazeutika / Large Cap /
878,40 €
-6,42 %
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target lowered by analysts at Guggenheim from $1,163.00 to $1,161.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at TD Cowen from $960.00 to $1,250.00. They now have a "buy" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Morgan Stanley from $1,290.00 to $1,313.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Cantor Fitzgerald from $985.00 to $1,205.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Scotiabank.
Ratings data for LLY provided by MarketBeat
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at JPMorgan Chase & Co. from $1,150.00 to $1,300.00. They now have an "overweight" rating on the stock.
Ratings data for LLY provided by MarketBeat
Neueste Beiträge
JPMorgan_Chase___Co_ in Boston Scientific diskutieren